Frequent mutations of the IDH1 have also been identified in hormone receptor-positive (HR+) breast adenocarcinoma, thyroid cancer, cholangiocarcinoma (50–70%), and IDH2 (R172S) in benign giant cell tumors of the bone (80%) (17, 19–22). The gene discussed is IDH1; the disease is cholangiocarcinoma.